Intuitive Surgical, Inc. (ISRG) — Fundamental Analysis
Snapshot & Big Picture
Intuitive Surgical is the dominant force in robotic-assisted surgery, best known for its da Vinci surgical system. The company operates a razor-and-blades business model: it places robotic systems at hospitals and earns recurring revenue from instruments, accessories, and service contracts with every procedure performed. This model creates deep customer stickiness — once a hospital trains its surgeons on a da Vinci platform, switching costs are enormous. Over the past three fiscal years, Intuitive has grown revenue from roughly $7.1 billion to over $10 billion, reflecting both growing procedure volumes and an expanding installed base worldwide.
Latest Quarter Snapshot
The most recent data available is from the 10-Q filed April 22, 2026, covering the quarter ended March 31, 2026. This is more current than the annual figures and provides the freshest read on the business.
| Metric | Q1 2026 (Period Ending Mar 31, 2026) |
|---|---|
| Revenue | $2.77 billion |
| Gross Margin | 66.1% |
| Operating Margin | 30.9% |
| Net Margin | 29.6% |
| Current Ratio | 4.61x |
| Debt-to-Equity | 0.14x |
| EBITDA | Not reported in filing |
At an annualized run rate, Q1 2026 revenue of $2.77 billion implies full-year revenue approaching or exceeding $11 billion if momentum holds. Operating margins of nearly 31% in a single quarter suggest continued operating leverage as the installed base grows and higher-margin recurring revenues (instruments and services) make up a larger share of the mix.
Profitability — Multi-Year Trend
Profitability has been on a clear upward trajectory. Both operating and net margins have expanded meaningfully over the three-year annual window, and gross margins have remained consistently above 66%. EBITDA was not separately disclosed in any of the filings provided.
| Fiscal Year | Revenue | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|---|
| 2023 | $7.12 billion | 66.4% | 24.8% | 25.2% |
| 2024 | $8.35 billion | 67.5% | 28.1% | 27.8% |
| 2025 | $10.06 billion | 66.0% | 29.3% | 28.4% |
Operating margin improved from 24.8% in 2023 to 29.3% in 2025 — a gain of roughly 450 basis points in two years. Net margin followed a nearly identical path, rising from 25.2% to 28.4%. Gross margin dipped very slightly in 2025 (from 67.5% to 66.0%) but has been remarkably stable across all periods, including the most recent quarter, suggesting no meaningful deterioration in pricing power or input cost pressure. The widening gap between gross margin and operating margin closing in — i.e., operating expenses growing more slowly than revenue — is classic operating leverage at work.
Financial Health
Intuitive Surgical carries one of the cleanest balance sheets in large-cap medtech. Its debt-to-equity ratio has hovered in a very narrow range across all periods, and its current ratio comfortably exceeds 4x, indicating the company holds substantial liquid assets relative to near-term obligations.
| Period | Current Ratio | Debt-to-Equity |
|---|---|---|
| FY 2023 | 4.76x | 0.15x |
| FY 2024 | 4.07x | 0.13x |
| FY 2025 | 4.87x | 0.14x |
| Q1 2026 | 4.61x | 0.14x |
A debt-to-equity ratio consistently around 0.14x is exceptionally low for a capital-intensive medical device manufacturer. This means Intuitive is almost entirely equity-financed and faces minimal refinancing or interest-rate risk. The high current ratio reflects substantial cash and short-term investment reserves, giving the company ample flexibility for R&D spending, strategic acquisitions, or share repurchases without needing external financing.
Growth
Revenue growth has been robust and accelerating in absolute dollar terms. The company crossed the $10 billion revenue threshold in fiscal year 2025, and the Q1 2026 quarterly result of $2.77 billion already represents a meaningful step above the average quarterly run rate implied by the full-year 2025 figure of roughly $2.52 billion per quarter.
| Period | Revenue | Year-over-Year Growth |
|---|---|---|
| FY 2023 | $7.12 billion | — |
| FY 2024 | $8.35 billion | +17.3% |
| FY 2025 | $10.06 billion | +20.5% |
| Q1 2026 (annualized) | ~$11.08 billion pace | Trending higher |
Growth has been driven by a combination of procedure volume increases, new system placements (including the newer da Vinci 5 platform), and international market expansion. Revenue growth actually accelerated from 17.3% in 2024 to 20.5% in 2025, which is a rare and positive signal for a company already generating over $8 billion annually. The Q1 2026 data suggests this trajectory has not materially reversed heading into 2026.
Plain English Summary
Intuitive Surgical is a high-quality, capital-light business that has compounded revenue at roughly 19% per year over the past two fiscal years while simultaneously expanding its profit margins — a combination that is genuinely difficult to find at this scale. The company is nearly debt-free, holds a fortress balance sheet with over 4.6x more current assets than current liabilities, and generates substantial net income on every dollar of revenue (nearly 30 cents as of the most recent quarter). Its recurring-revenue model — where hospitals pay for instruments and service on every surgery performed — means earnings are far more predictable and resilient than a pure hardware seller. The most recent quarterly filing shows no signs of margin compression or growth slowdown; if anything, operating margins in Q1 2026 reached their highest level in the data set. The key risks to monitor would be competitive pressure from emerging robotic surgery platforms, hospital capital spending cycles that could slow system placements, and potential regulatory headwinds — none of which are reflected in the financials shown here, but all of which are worth watching. On the numbers alone, Intuitive Surgical presents a picture of a financially sound, growing, and increasingly profitable business.
Leave a Comment